GLB-007
/ GluBio Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 12, 2026
Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
(flcube.com)
- "The funding will advance GluBio’s two core sickle cell disease programs-GLB-005 and GLB-007-oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026."
Financing • New P1 trial • Sickle Cell Disease
1 to 1
Of
1
Go to page
1